β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer
Abstract Background Adherent junction associated protein 1 (AJAP1), a typical molecule of adherent junctions, has been found to be a tumor suppressor in many cancer types. Aberrant activation of β-catenin has been demonstrated to be associated with malignant biological properties of tumors including...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1252-6 |
id |
doaj-399d3cb3d3934303a7d0e19cc779e591 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cong Xu Fang Liu Guomin Xiang Lu Cao Shuling Wang Jing Liu Qingxiang Meng Danni Xu Shuhua Lv Jiao Jiao Yun Niu |
spellingShingle |
Cong Xu Fang Liu Guomin Xiang Lu Cao Shuling Wang Jing Liu Qingxiang Meng Danni Xu Shuhua Lv Jiao Jiao Yun Niu β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer Journal of Experimental & Clinical Cancer Research AJAP1 β-Catenin Nuclear location EGF EGFR Tumor progression |
author_facet |
Cong Xu Fang Liu Guomin Xiang Lu Cao Shuling Wang Jing Liu Qingxiang Meng Danni Xu Shuhua Lv Jiao Jiao Yun Niu |
author_sort |
Cong Xu |
title |
β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer |
title_short |
β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer |
title_full |
β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer |
title_fullStr |
β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer |
title_full_unstemmed |
β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer |
title_sort |
β-catenin nuclear localization positively feeds back on egf/egfr-attenuated ajap1 expression in breast cancer |
publisher |
BMC |
series |
Journal of Experimental & Clinical Cancer Research |
issn |
1756-9966 |
publishDate |
2019-06-01 |
description |
Abstract Background Adherent junction associated protein 1 (AJAP1), a typical molecule of adherent junctions, has been found to be a tumor suppressor in many cancer types. Aberrant activation of β-catenin has been demonstrated to be associated with malignant biological properties of tumors including breast cancer. This study aimed to investigate the function and mechanism of AJAP1-mediated β-catenin activity of breast cancer lines in vitro and in breast cancer patients. Methods AJAP1 and β-catenin expressions in breast cancer tissues and cell lines were detected by immunohistochemistry, western blotting and qRT-PCR. The EGF/EGFR axis-mediated AJAP1 attenuated β-catenin nuclear location was measured by western blotting, immunofluorescence assay, co-immunoprecipitation, luciferase assay and ubiquitination assays. Furthermore, the function of AJAP1 and β-catenin regulated breast cancer progression was explored both in vivo and in vitro. Results It was found that AJAP1 had a high negative correlation with β-catenin nuclear expression and was a novel tumor suppressor in breast cancer. AJAP1 loss can mediate β-catenin accumulated in cytoplasm and then transferred it to the nucleus, activating β-catenin transcriptional activity and downstream genes. Additionally, β-catenin can reverse the invasion, proliferation ability and tumorigenicity of the depletion of AJAP1 caused both in vivo and in vitro. Besides, EGF/EGFR also involved in the process of AJAP1-depiction induced β-catenin transactivation to the nucleus. More importantly, EGFR depletion/AJAP1 knocked down promoted the progression of breast cancer by regulating the activity of β-catenin nuclear transactivation. Conclusion This study demonstrated that AJAP1 acted as a putative tumor suppressor while β-catenin nuclear localization positively fed back on EGF/EGFR-attenuated AJAP1 expression in breast cancer, which might be beneficial to develop new therapeutic targets for decreasing nuclear β-catenin-mediated malignancy in breast cancer. |
topic |
AJAP1 β-Catenin Nuclear location EGF EGFR Tumor progression |
url |
http://link.springer.com/article/10.1186/s13046-019-1252-6 |
work_keys_str_mv |
AT congxu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT fangliu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT guominxiang bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT lucao bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT shulingwang bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT jingliu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT qingxiangmeng bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT dannixu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT shuhualv bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT jiaojiao bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer AT yunniu bcateninnuclearlocalizationpositivelyfeedsbackonegfegfrattenuatedajap1expressioninbreastcancer |
_version_ |
1724746364400697344 |
spelling |
doaj-399d3cb3d3934303a7d0e19cc779e5912020-11-25T02:48:50ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662019-06-0138111610.1186/s13046-019-1252-6β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancerCong Xu0Fang Liu1Guomin Xiang2Lu Cao3Shuling Wang4Jing Liu5Qingxiang Meng6Danni Xu7Shuhua Lv8Jiao Jiao9Yun Niu10Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerDepartment of Pathology, Tianjin Union Medical Center, Tianjin People’s HospitalTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for CancerAbstract Background Adherent junction associated protein 1 (AJAP1), a typical molecule of adherent junctions, has been found to be a tumor suppressor in many cancer types. Aberrant activation of β-catenin has been demonstrated to be associated with malignant biological properties of tumors including breast cancer. This study aimed to investigate the function and mechanism of AJAP1-mediated β-catenin activity of breast cancer lines in vitro and in breast cancer patients. Methods AJAP1 and β-catenin expressions in breast cancer tissues and cell lines were detected by immunohistochemistry, western blotting and qRT-PCR. The EGF/EGFR axis-mediated AJAP1 attenuated β-catenin nuclear location was measured by western blotting, immunofluorescence assay, co-immunoprecipitation, luciferase assay and ubiquitination assays. Furthermore, the function of AJAP1 and β-catenin regulated breast cancer progression was explored both in vivo and in vitro. Results It was found that AJAP1 had a high negative correlation with β-catenin nuclear expression and was a novel tumor suppressor in breast cancer. AJAP1 loss can mediate β-catenin accumulated in cytoplasm and then transferred it to the nucleus, activating β-catenin transcriptional activity and downstream genes. Additionally, β-catenin can reverse the invasion, proliferation ability and tumorigenicity of the depletion of AJAP1 caused both in vivo and in vitro. Besides, EGF/EGFR also involved in the process of AJAP1-depiction induced β-catenin transactivation to the nucleus. More importantly, EGFR depletion/AJAP1 knocked down promoted the progression of breast cancer by regulating the activity of β-catenin nuclear transactivation. Conclusion This study demonstrated that AJAP1 acted as a putative tumor suppressor while β-catenin nuclear localization positively fed back on EGF/EGFR-attenuated AJAP1 expression in breast cancer, which might be beneficial to develop new therapeutic targets for decreasing nuclear β-catenin-mediated malignancy in breast cancer.http://link.springer.com/article/10.1186/s13046-019-1252-6AJAP1β-CateninNuclear locationEGFEGFRTumor progression |